Ensysce Biosciences (NASDAQ:ENSC) Releases Earnings Results, Beats Estimates By $0.37 EPS

Ensysce Biosciences (NASDAQ:ENSC) issued its quarterly earnings results on Tuesday. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.37, Zacks reports. Ensysce Biosciences had a negative return on equity of 559.68% and a negative net margin of 179.26%. The firm had revenue of $3.42 million for the quarter, compared to the consensus estimate of $0.25 million.

Ensysce Biosciences Trading Down 4.8 %

NASDAQ:ENSC opened at $0.68 on Thursday. The company has a market cap of $5.95 million, a price-to-earnings ratio of -0.39 and a beta of 0.63. Ensysce Biosciences has a twelve month low of $0.14 and a twelve month high of $2.06. The stock has a fifty day simple moving average of $0.36 and a 200-day simple moving average of $0.45.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.